For years, medications such as Mounjaro have been discussed primarily in the context of blood sugar control and weight loss.
That conversation just expanded.
On August 28, 2026, the U.S. Food and Drug Administration approved Mounjaro (tirzepatide) to reduce the risk of major cardiovascular events in adults with type 2 diabetes who are at high risk for those events.
The expanded indication includes reducing the risk of:
- Cardiovascular death
- Nonfatal heart attack
- Nonfatal stroke
This is significant because cardiovascular disease remains one of the most serious long-term complications associated with type 2 diabetes.
But the headlines deserve some context.
The new approval does not mean Mounjaro eliminates cardiovascular risk, nor does it mean every person taking tirzepatide should expect the same benefit.
Understanding who was studied, what the trial actually found, and how cardiovascular risk should be managed as part of a broader metabolic health strategy matters.
What Did the FDA Approve for Mounjaro?
Mounjaro is the brand name for tirzepatide, a once-weekly injectable medication that activates both:
- GIP, or glucose-dependent insulinotropic polypeptide, receptors
- GLP-1, or glucagon-like peptide-1, receptors
Mounjaro was originally FDA approved in 2022 to improve blood glucose control in adults with type 2 diabetes.
Its indication has since expanded.
The August 2026 approval allows Mounjaro to also be used to reduce the risk of major adverse cardiovascular events, or MACE, in adults with type 2 diabetes who are at high cardiovascular risk.
That is an important distinction.
This cardiovascular indication specifically concerns Mounjaro in adults with type 2 diabetes and elevated cardiovascular risk. It should not be interpreted as a blanket cardiovascular-prevention indication for everyone using tirzepatide.
Why Cardiovascular Risk Matters So Much in Type 2 Diabetes
Type 2 diabetes is not simply a blood sugar problem.
Over time, diabetes can affect the blood vessels, heart, kidneys, nerves, and other organs.
People with type 2 diabetes frequently have several cardiovascular risk factors at the same time, including:
- High blood pressure
- Elevated LDL cholesterol
- Insulin resistance
- Excess visceral fat
- Chronic inflammation
- Kidney disease
- Physical inactivity
- Obstructive sleep apnea
- Smoking history
Some people may also have cardiovascular disease without obvious symptoms.
That is why modern diabetes management has moved beyond simply asking:
“What is your A1C?”
A better question is:
“What is your total cardiometabolic risk, and what can we do to reduce it?”
The new Mounjaro indication fits into that broader approach.
What Was the SURPASS-CVOT Trial?
The FDA’s expanded cardiovascular indication was supported by results from SURPASS-CVOT, a large cardiovascular outcomes trial comparing tirzepatide directly with dulaglutide, sold under the brand name Trulicity.
This was not a small study.
More than 13,000 participants were randomized in the trial, which was conducted across hundreds of sites internationally. Participants had type 2 diabetes as well as established atherosclerotic cardiovascular disease.
Researchers compared:
Tirzepatide: up to 15 mg once weekly
with
Dulaglutide: 1.5 mg once weekly
Dulaglutide was an important comparator because it already had evidence of cardiovascular benefit.
The primary outcome was a three-part cardiovascular endpoint known as MACE-3, consisting of:
- Cardiovascular death
- Myocardial infarction, or heart attack
- Stroke
Participants were followed for approximately four years on average.
What Did the Trial Find?
A primary cardiovascular event occurred in:
12.2% of participants receiving tirzepatide
compared with
13.1% of participants receiving dulaglutide.
The reported hazard ratio was 0.92, with a 95.3% confidence interval of 0.83 to 1.01.
This corresponded to an observed 8% lower relative rate of cardiovascular death, heart attack, or stroke in the tirzepatide group compared with dulaglutide.
There is an important statistical detail, however.
Tirzepatide was noninferior, but not statistically superior
SURPASS-CVOT was designed first to determine whether tirzepatide was noninferior to dulaglutide for cardiovascular outcomes.
It met that endpoint.
In other words, tirzepatide demonstrated cardiovascular outcomes that were at least comparable within the study’s predefined statistical margin to a GLP-1 medication already known to provide cardiovascular benefit.
Although the event rate was numerically 8% lower with tirzepatide, the trial did not establish statistical superiority over dulaglutide for the primary MACE-3 endpoint.
That nuance matters when interpreting headlines about the study.
Why This Approval Is Important
The significance of this approval is not simply that another GLP-1-related medication can help with cardiovascular risk.
Tirzepatide works differently from traditional GLP-1 receptor agonists because it targets both GIP and GLP-1 receptors.
The expanded indication now adds cardiovascular risk reduction to Mounjaro’s established role in improving glycemic control for appropriate patients with type 2 diabetes.
That reflects a larger shift in metabolic medicine.
Treatment is increasingly moving away from addressing blood glucose, body weight, blood pressure, cholesterol, and cardiovascular disease as completely separate problems.
These systems are interconnected.
For many patients, the goal should be comprehensive cardiometabolic health.
Does This Mean Mounjaro Is a Heart Medication?
Not exactly.
Mounjaro remains a medication used primarily in the management of type 2 diabetes, with an expanded indication for cardiovascular risk reduction in certain adults with type 2 diabetes.
It should not replace comprehensive cardiovascular prevention.
Depending on the individual, cardiovascular risk management may still include:
- Blood pressure management
- LDL cholesterol reduction
- Appropriate lipid-lowering medication
- Smoking cessation
- Regular physical activity
- Resistance training
- Nutrition changes
- Blood glucose management
- Sleep apnea evaluation
- Weight management
- Kidney health monitoring
- Appropriate cardiovascular screening
Medication can be powerful, but it should be viewed as one part of the overall strategy.
Does the Approval Apply to Zepbound Too?
This is another important distinction.
Both Mounjaro and Zepbound contain tirzepatide, but they are FDA-approved under different indications.
Mounjaro is primarily indicated for type 2 diabetes.
Zepbound is indicated for chronic weight management in qualifying individuals and has additional approved indications separate from Mounjaro.
The August 2026 cardiovascular approval discussed here specifically applies to Mounjaro for adults with type 2 diabetes who are at high risk for major cardiovascular events.
Patients should not assume that an FDA indication associated with one tirzepatide brand automatically applies to every use of the molecule.
What Are the Risks and Side Effects of Mounjaro?
Like any prescription medication, Mounjaro is not appropriate for everyone.
Gastrointestinal side effects are among the most commonly reported issues with tirzepatide.
These may include:
- Nausea
- Diarrhea
- Decreased appetite
- Vomiting
- Constipation
- Abdominal discomfort
In SURPASS-CVOT, gastrointestinal adverse events were more common with tirzepatide and generally occurred during dose escalation.
Mounjaro also carries a boxed warning related to thyroid C-cell tumors observed in animal studies. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or those with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Other potentially serious risks require medical consideration and monitoring.
This is one reason GLP-1 and GIP/GLP-1 medications should be prescribed and monitored as part of appropriate clinical care rather than viewed simply as weight-loss products.
Cardiovascular Health Is Bigger Than a Single Medication
One of the most useful lessons from this approval may have little to do with any individual medication.
Cardiovascular disease develops from multiple interacting factors.
For someone with type 2 diabetes, evaluating heart health may involve looking at much more than body weight.
Depending on the individual, clinicians may consider:
Blood pressure
Consistently elevated blood pressure can significantly increase cardiovascular risk.
Lipid markers
LDL cholesterol, triglycerides, HDL cholesterol, and in some situations ApoB and lipoprotein(a), may provide useful information about cardiovascular risk.
Glucose regulation
A1C, fasting glucose, and other metabolic indicators help provide context around diabetes management.
Kidney health
Kidney disease and cardiovascular disease are closely connected, particularly in people with diabetes.
Body composition
Where fat is stored and how much lean muscle a person maintains can matter beyond the number on the scale.
Sleep
Untreated sleep apnea can contribute to high blood pressure, insulin resistance, fatigue, and cardiovascular stress.
Physical fitness
Cardiorespiratory fitness and strength are meaningful markers of long-term health.
This is why focusing only on weight loss can miss part of the picture.
What This Means for Patients Using Tirzepatide
If you are already taking Mounjaro, this FDA approval does not necessarily mean your treatment needs to change.
If you have type 2 diabetes and significant cardiovascular risk, however, the new indication may provide another factor for you and your healthcare provider to consider when evaluating treatment options.
The right medication still depends on your individual:
- Medical history
- Diabetes status
- Cardiovascular history
- Current medications
- Kidney function
- Gastrointestinal history
- Treatment goals
- Side-effect tolerance
- Laboratory results
- Contraindications
There is no universal “best GLP-1.”
The best treatment is the one that fits the clinical situation and can be used safely and consistently.
The Bigger Shift: From Weight Loss to Metabolic Risk Reduction
GLP-1 medications initially gained enormous public attention because of their effects on body weight.
But their clinical story is increasingly about much more than the scale.
For appropriate patients, metabolic treatment may affect several interconnected areas:
- Blood glucose
- Body weight
- Cardiovascular risk
- Blood pressure
- Lipids
- Inflammation
- Kidney health
- Overall metabolic health
That does not mean one medication solves every one of these problems.
It means metabolic health should be evaluated as a connected system.
At 1st Optimal, we believe medication decisions make more sense when they are paired with a broader understanding of the person.
That may include laboratory testing, body composition, nutrition, exercise, sleep, hormone health, cardiovascular risk factors, and ongoing clinical monitoring.
The Bottom Line
The FDA’s August 2026 expansion of Mounjaro’s indication represents an important development in type 2 diabetes treatment.
Mounjaro can now be used to reduce the risk of cardiovascular death, nonfatal heart attack, and nonfatal stroke in adults with type 2 diabetes who are at high risk for these events.
The approval was supported by the large SURPASS-CVOT trial.
In that study, tirzepatide was noninferior to dulaglutide, an established GLP-1 therapy with cardiovascular benefit, for preventing major cardiovascular events. The tirzepatide group experienced an observed 8% lower event rate, although statistical superiority over dulaglutide was not established.
The takeaway should not be that everyone needs Mounjaro.
It should be that diabetes treatment is increasingly becoming cardiometabolic treatment.
Blood sugar matters.
Body composition matters.
Heart health matters.
And the best strategy considers all of them together.
Want to Understand Your Metabolic Health More Clearly?
At 1st Optimal, we take a comprehensive approach to metabolic health, weight management, hormone health, laboratory testing, nutrition, and long-term performance.
Rather than focusing on one symptom or one laboratory value, our clinical team looks at the broader picture to help determine what may be appropriate for your individual goals and medical history.
Explore 1st Optimal Functional Health Plans:
https://1stoptimal.com/functionalhealthplans/
Book a Health Consult:
https://1stoptimal.com/book-a-call/
This article is for educational purposes only and is not intended as medical advice. Prescription medications require evaluation by a qualified healthcare professional. Eligibility, treatment selection, risks, benefits, and monitoring should be determined individually.
Frequently Asked Questions
Is Mounjaro FDA approved to reduce cardiovascular risk?
Yes. In August 2026, the FDA approved Mounjaro to reduce the risk of major cardiovascular events, including cardiovascular death, nonfatal heart attack, and nonfatal stroke, in adults with type 2 diabetes who are at high risk for those events.
How much did Mounjaro reduce cardiovascular events?
In SURPASS-CVOT, major cardiovascular events occurred in 12.2% of participants receiving tirzepatide versus 13.1% receiving dulaglutide. This represented an observed 8% lower relative rate. However, tirzepatide demonstrated statistical noninferiority rather than superiority to dulaglutide for the trial’s primary cardiovascular endpoint.
What was SURPASS-CVOT?
SURPASS-CVOT was a randomized cardiovascular outcomes trial involving more than 13,000 people with type 2 diabetes and established atherosclerotic cardiovascular disease. It compared tirzepatide with dulaglutide and evaluated cardiovascular death, heart attack, and stroke.
Is Mounjaro the same as Zepbound?
Both medications contain tirzepatide, but they have different FDA-approved indications. The cardiovascular indication discussed in this article applies specifically to Mounjaro in qualifying adults with type 2 diabetes.
Is Mounjaro a GLP-1 medication?
Mounjaro activates GLP-1 receptors, but unlike medications that target only GLP-1, tirzepatide also activates GIP receptors. It is therefore commonly described as a dual GIP/GLP-1 receptor agonist.
Should I take Mounjaro to prevent heart disease?
That decision requires an individualized medical evaluation. Cardiovascular history, type 2 diabetes status, medications, laboratory findings, contraindications, side effects, and other risk factors all need to be considered.
References
- Eli Lilly and Company. FDA Approves Lilly’s Mounjaro (tirzepatide) to Reduce Cardiovascular Risk in Adults With Type 2 Diabetes. BioSpace. Published August 28, 2026.
- Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. New England Journal of Medicine. 2025;393:2409-2420. doi:10.1056/NEJMoa2505928.
- U.S. Food and Drug Administration. Mounjaro (tirzepatide) Prescribing Information. FDA. Updated 2026.
- Eli Lilly and Company. Mounjaro (tirzepatide) U.S. Prescribing Information and Safety Information. Lilly USA, LLC.
- U.S. Food and Drug Administration. Drug Approval Package: Mounjaro (tirzepatide). FDA Center for Drug Evaluation and Research.
- ClinicalTrials.gov. A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT). Identifier: NCT04255433.
